Loading doses for costly cancer biologicals: a cause for concern or tilting at windmills?
| Autor: | Ivo M. Hennig, Chris Twelves |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Cancer Research
medicine.medical_specialty Biological therapies Biological Products Cost effectiveness business.industry Cancer Context (language use) Antineoplastic Agents medicine.disease Drug Administration Schedule Drug Costs Surgery Clinical trial Oncology Neoplasms medicine Humans Intensive care medicine Treatment costs business |
| Zdroj: | European journal of cancer (Oxford, England : 1990). 44(11) |
| ISSN: | 0959-8049 |
| Popis: | The emergence of novel, effective but expensive biological therapies is significantly improving outcomes for many patients with cancer, but also substantially increasing treatment costs. Monoclonal antibodies with long half-lives have often been developed using loading doses to hasten the achievement of a therapeutic dose. Although the benefits of loading doses have not been proven, we caution against abandoning this practice on uncertain theoretical grounds. Rather, the issue of loading doses should be seen in the broader context of how best to define the optimal dose, schedule and duration of treatment through novel clinical trial designs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect